Log In Get Started
Press Releases October 5, 2026 09:45 AM

Alpha Tau to Participate in October Investor Conferences

Alpha Tau Medical to Present at Key Investor Conferences in October 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
DRTS

Alpha Tau Medical Ltd., an Israeli oncology therapeutics firm developing the Alpha DaRT alpha-radiation cancer therapy, announced participation in two prominent investor conferences in October 2026, aiming to engage with investors and showcase its innovative solid tumor treatment technology.

Alpha Tau to Participate in October Investor Conferences
DRTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alpha Tau Medical focuses on developing Alpha DaRT, a novel alpha-radiation therapy targeting solid tumors, designed to deliver localized high-energy alpha particles to spare healthy tissue.
  • Company management will attend the Barclays Biotech 1x1 Day in New York and present at the Investment Generation Conference in Israel during October 2026.
  • Alpha DaRT's technology involves intratumoral delivery of radium-224 impregnated sources and leverages short-range alpha particle emissions to destroy tumors effectively.

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.

Event:Fall Focus: Barclays Biotech 1x1 DayFormat:1x1 MeetingsDate:Tuesday, October 6, 2026Location:New York, NY

  

Event:Investment Generation ConferenceFormat:PresentationDate:Thursday, October 15, 2026Time:12:30 – 1:00 PMLocation:Rishon Letzion, Israel


About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:

[email protected]


Risks

  • The therapy is still under research and development, with associated uncertainties in clinical efficacy and regulatory approvals impacting commercialization timelines.
  • Market adoption depends on successful demonstration of safety and superiority over existing cancer treatments in competitive oncology sectors.
  • Potential operational risks related to scaling production and managing international collaborations given the company’s Israeli origin and US listing.

More from Press Releases

Super League and Panda Express Prove Gaming Drives Full-Funnel Brand Impact, Evolving Initial Campaign into Always-On Marketing Platform Oct 5, 2026 Hunter Fan Company Expands Jasmine Roth Lighting Collection Oct 5, 2026 Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 Oct 5, 2026 LKQ Corporation to Release Third Quarter 2026 Results on Thursday, October 29, 2026 Oct 5, 2026 Uniti Fiber and New Orleans Saints Announce Fiber-Backed Partnership to Support Connected Gameday and Business Operations Oct 5, 2026